Payment overview · 2025
General Payments
$179.00
10 reported records · 6 companies
Healthcare provider profile · identity verified
Rozella Ranes, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1902876568
Verified facts
What the public records show
CMS Open Payments records show Rozella Ranes, MD received $179.00 in general payments during 2025 across 10 reported records.
VERTEX PHARMACEUTICALS INCORPORATED accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $33.28 | 18.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.69 | 18.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.93 | 17.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.59 | 17.6% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $29.03 | 16.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $20.48 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $179.00 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 265 | 73 |
| Losartan Potassium | Losartan Potassium | 254 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 68 |
| Lisinopril | Lisinopril | 209 | 63 |
| Omeprazole | Omeprazole | 203 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 44 |
| Montelukast Sodium | Montelukast Sodium | 136 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 76 |
| Gabapentin | Gabapentin | 127 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 43 |
| Simvastatin | Simvastatin | 122 | 33 |
| Lovastatin | Lovastatin | 121 | 33 |
| Potassium Chloride | Potassium Chloride | 110 | 35 |
| Famotidine | Famotidine | 95 | 28 |
| Ozempic | Semaglutide | 92 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 22 |
| Meloxicam | Meloxicam | 88 | 31 |
| Sertraline Hcl | Sertraline Hcl | 82 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 24 |
| Trazodone Hcl | Trazodone Hcl | 75 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 23 |
| Alprazolam | Alprazolam | 67 | 30 |
| Metformin Hcl | Metformin Hcl | 67 | 22 |
| Carvedilol | Carvedilol | 65 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Furosemide | Furosemide | 61 | 24 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 54 | 54 |
| Tramadol Hcl | Tramadol Hcl | 54 | 27 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Celecoxib | Celecoxib | 49 | 13 |
| Prednisone | Prednisone | 47 | 44 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Spironolactone | Spironolactone | 42 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Valacyclovir | Valacyclovir Hcl | 34 | 13 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Estradiol | Estradiol | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | 11 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 16 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Atenolol | Atenolol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $179.00 · 10 records | VERTEX PHARMACEUTICALS INCORPORATED | CeQur Simplicity, JOURNAVX, LINZESS, NURTEC ODT, QULIPTA, Senza, UBRELVY, Veozah, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error